Carnegie Lake Advisors’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$451K Buy
390
+19
+5% +$22.4K 0.17% 116
2026
Q2
$445K Hold
371
– – 0.17% 116
2026
Q1
$341K Hold
371
– – 0.14% 129
2025
Q4
$399K Hold
371
– – 0.15% 117
2025
Q3
$283K Hold
371
– – 0.11% 138
2025
Q2
$289K Hold
371
– – 0.11% 128
2025
Q1
$306K Hold
371
– – 0.12% 121
2024
Q4
$286K Hold
371
– – 0.12% 121
2024
Q3
$329K Buy
+371
New +$334K 0.13% 114

Other funds holding LLY

Carnegie Lake Advisors's LLY Position: Q3 2026 in Review

Carnegie Lake Advisors increased its Eli Lilly (LLY) stake by 5.1% in Q3 2026, buying an estimated $22.4K and bringing the position to 390 shares worth $451K. The position accounts for 0.17% of the portfolio, ranked #116.

Carnegie Lake Advisors first reported a position in LLY in Q3 2024 and has held it in 9 quarters since. 4,065 funds tracked by Wall St. Rank hold LLY as of Q3 2026.

  • Carnegie Lake Advisors held 390 shares of Eli Lilly worth $451K as of Q3 2026.
  • Carnegie Lake Advisors bought 19 Eli Lilly shares in Q3 2026, an estimated $22.4K.
  • Eli Lilly made up 0.17% of Carnegie Lake Advisors's portfolio in Q3 2026, its #116 holding.
  • Carnegie Lake Advisors first reported a position in Eli Lilly in Q3 2024 and has held it in 9 quarters since.
  • 4,065 funds tracked by Wall St. Rank held Eli Lilly as of Q3 2026.

Based on Carnegie Lake Advisors's 13F filing for Q3 2026, filed 3 Nov 2026.